Search

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

Jun 14 2013

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Killer antibodies against AML

Jun 11 2016 Posted in Press releases

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

Jun 13 2014 Posted in Press releases

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Jun 10 2016

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Genome sequencing of thousands of patients with rare blood disorders

Jun 11 2016 Posted in Press releases

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.